Articles

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, and for the treatment of…

The AACR-Debbie’s Dream Foundation Career Development Award for Gastric Cancer Research represents a joint effort to encourage and support junior faculty to conduct gastric cancer research and to establish a successful career path in this field. Learn More>

Gastrectomy causes vitamin B-12 deficiency since vitamin B-12 requires gastric acid and intrinsic factor for its absorption. Vitamin B-12 deficiency is considered to develop years after gastrectomy because of large hepatic storage. However, most gastric cancer develops after long-standing atrophic gastritis with vitamin B-12 malabsorption. We have investigated vita-min B-12 status in 22 patients before…

Older adults with gastrointestinal cancers who had inadequate emotional support were more likely to have poor physical and mental health-related quality of life, in addition to depression, compared to those with adequate emotional support, according to findings from a recent study. Of note, the patients with and without adequate emotional support did not have major…

Imugene Ltd (ASX:IMU, OTC:IUGNF) has presented new and significant data on HER-Vaxx at the World Congress of Gastrointestinal Cancer in Barcelona. Read More>

Merck’s cancer star Keytruda could be on its way to an updated label in HER2-positive stomach cancer after showing it can stave off tumor progression in a combination study. Read more>

Gastric cancer ranks as the fourth leading cause of cancer-related deaths worldwide and the third in China. The overall five-year survival rate stands at approximately 20%. Radical gastrectomy has emerged as a prominent approach in the comprehensive treatment of gastric cancer, aiming to achieve a cure. Over time, advancements in clinical research have led to…

Summary Patients with upper GI cancers are in dire need of new therapeutic options. Astellas is sitting on a shoo-in approval for a brand new targeted therapy based on highly promising clinical trial data. An approval in this space could mean important new revenue inroads for the company. Read More>

CLAUDIN-18 Splice Variant 2 (claudin-18.2; CLDN18.2) has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer (GC), gastroesophageal junction (GEJ) cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies.1 Multiple clinical trials of CLDN18.2-targeted therapies, including…

The FDA has granted orphan drug designation to ATG-022, a Claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC), for the treatment of patients with gastric cancer and pancreatic cancer, according to a press release from developer Antengene Corporation Limited.1